Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.
You may also be interested in...
Xeloda Combination Studies Get Combined NCCN/Roche Support
Nine National Comprehensive Cancer Network studies are examining the cancer therapy Xeloda in solid tumors.
Xeloda Combination Studies Get Combined NCCN/Roche Support
Nine National Comprehensive Cancer Network studies are examining the cancer therapy Xeloda in solid tumors.
Roche's Xeloda Gains Approval For Adjuvant Colon Cancer
FDA approves capecitabine for adjuvant treatment in patients with Dukes' C colon cancer. Roche is positioning Xeloda as an oral alternative to intravenous 5-fluorouracil/leucovorin-based chemotherapy.